Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

Gilead Sciences (NasdaqGS:GILD) recently announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, ...

(Nasdaq: GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

Combining Trodelvy with Keytruda and pushing it into the frontline setting could “potentially double” the ADC’s market in ...

Gilead Sciences on Thursday reported slightly higher-than-expected quarterly earnings on flat revenue, as higher sales of ...

Gilead Sciences has shared positive top-line results from a late-stage study evaluating its antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) with Merck & Co’s anti-PD-1 therapy ...

Gain key insights from Gilead Sciences' Q1 2025 earnings call, featuring strong HIV sales, Lenacapavir launch updates, and market trends shaping ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

(Reuters) -Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for ...

The study enrolled patients with a PD-L1 combined positive score (CPS) of 10 or more, matching Keytruda's label in first-line ...